HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 193 filers reported holding HAEMONETICS CORP in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,770,844 | -20.2% | 30,932 | -24.2% | 0.00% | 0.0% |
Q2 2023 | $3,474,265 | +53.8% | 40,807 | +49.5% | 0.00% | 0.0% |
Q1 2023 | $2,259,116 | +104.5% | 27,300 | +94.4% | 0.00% | – |
Q4 2022 | $1,104,638 | -6.0% | 14,045 | -11.6% | 0.00% | – |
Q3 2022 | $1,175,000 | +36.3% | 15,883 | +20.1% | 0.00% | – |
Q2 2022 | $862,000 | -78.4% | 13,220 | -79.1% | 0.00% | -100.0% |
Q1 2022 | $3,990,000 | +14.3% | 63,107 | -4.1% | 0.00% | 0.0% |
Q4 2021 | $3,492,000 | -86.8% | 65,830 | -82.5% | 0.00% | -83.3% |
Q3 2021 | $26,529,000 | -20.8% | 375,821 | -25.2% | 0.01% | -14.3% |
Q2 2021 | $33,476,000 | -45.2% | 502,329 | -8.8% | 0.01% | -50.0% |
Q1 2021 | $61,118,000 | -57.7% | 550,572 | -54.7% | 0.01% | -60.0% |
Q4 2020 | $144,404,000 | +59.8% | 1,216,040 | +17.4% | 0.04% | +40.0% |
Q3 2020 | $90,384,000 | +16.7% | 1,035,931 | +19.8% | 0.02% | +8.7% |
Q2 2020 | $77,439,000 | -0.1% | 864,665 | +11.1% | 0.02% | -14.8% |
Q1 2020 | $77,550,000 | -4.7% | 778,143 | +9.8% | 0.03% | +22.7% |
Q4 2019 | $81,397,000 | -29.7% | 708,413 | -22.9% | 0.02% | -33.3% |
Q3 2019 | $115,866,000 | -14.4% | 918,539 | -18.4% | 0.03% | -15.4% |
Q2 2019 | $135,416,000 | +61.3% | 1,125,267 | +17.3% | 0.04% | +56.0% |
Q1 2019 | $83,953,000 | -6.5% | 959,681 | +6.9% | 0.02% | -16.7% |
Q4 2018 | $89,790,000 | -7.2% | 897,443 | +6.3% | 0.03% | +11.1% |
Q3 2018 | $96,708,000 | -0.5% | 844,031 | -22.1% | 0.03% | -6.9% |
Q2 2018 | $97,209,000 | -30.6% | 1,083,959 | -43.4% | 0.03% | -29.3% |
Q1 2018 | $140,122,000 | +13.9% | 1,915,288 | -9.6% | 0.04% | +13.9% |
Q4 2017 | $122,996,000 | -0.7% | 2,117,705 | -23.3% | 0.04% | -5.3% |
Q3 2017 | $123,816,000 | +12.5% | 2,759,457 | -1.0% | 0.04% | +8.6% |
Q2 2017 | $110,104,000 | +6.4% | 2,788,122 | +9.3% | 0.04% | +2.9% |
Q1 2017 | $103,446,000 | +10.3% | 2,549,828 | +9.3% | 0.03% | +3.0% |
Q4 2016 | $93,746,000 | +10.2% | 2,331,992 | -0.8% | 0.03% | +6.5% |
Q3 2016 | $85,080,000 | +10.0% | 2,349,633 | -11.9% | 0.03% | +3.3% |
Q2 2016 | $77,328,000 | +8.0% | 2,667,384 | +30.3% | 0.03% | +3.4% |
Q1 2016 | $71,597,000 | -2.8% | 2,046,813 | -10.4% | 0.03% | 0.0% |
Q4 2015 | $73,667,000 | -6.4% | 2,284,959 | -6.2% | 0.03% | -12.1% |
Q3 2015 | $78,744,000 | -19.1% | 2,436,384 | +3.6% | 0.03% | -13.2% |
Q2 2015 | $97,299,000 | -7.5% | 2,352,495 | +0.4% | 0.04% | +90.0% |
Q1 2015 | $105,202,000 | +153.0% | 2,341,986 | +110.8% | 0.02% | +25.0% |
Q4 2014 | $41,575,000 | +69.3% | 1,111,038 | +58.0% | 0.02% | +60.0% |
Q3 2014 | $24,556,000 | +9.6% | 703,201 | +10.7% | 0.01% | +11.1% |
Q2 2014 | $22,409,000 | +8.2% | 635,145 | -0.0% | 0.01% | 0.0% |
Q1 2014 | $20,705,000 | -47.0% | 635,330 | -31.5% | 0.01% | -47.1% |
Q4 2013 | $39,079,000 | +1.6% | 927,586 | -3.8% | 0.02% | -5.6% |
Q3 2013 | $38,446,000 | +1.6% | 964,051 | +5.4% | 0.02% | -10.0% |
Q2 2013 | $37,836,000 | – | 915,034 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |